Investigating how the dengue vaccine works in people with prior dengue infection
Official title: Immunogenicity of the dengue vaccine CYD-TDV in a dengue virus serotype 1 immune population
Funded at Oregon Health & Science University · NIH-10892299 · Data updated 2026-11-12
This study is looking at how the dengue vaccine works better for people who have had dengue before, and it aims to find out why that is, so we can make the vaccine even more effective for everyone.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | July 21, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $195,042 |
| NIH project number | 5R21AI178617-02 |
| Project ID | NIH-10892299 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals aged 9-16 years who have a confirmed history of dengue virus infection.
✕Less likely to help
Patients who have never been infected with the dengue virus may not benefit from this research.
What this research studies
This research focuses on understanding the immune response generated by the dengue vaccine CYD-TDV in individuals who have previously been infected with the dengue virus. The study aims to explore why the vaccine is more effective in these individuals compared to those without prior infection. By examining the role of immune cells and antibodies, researchers hope to uncover mechanisms that enhance the vaccine's effectiveness. This could lead to improved vaccination strategies for dengue prevention.
Why it matters
Potential benefit: If successful, this research could lead to more effective dengue vaccination strategies, potentially reducing the incidence of dengue fever.
How similar studies have gone: Previous research has shown that understanding immune responses to vaccines can lead to significant advancements in vaccine efficacy, suggesting potential for success in this area.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Messer, William — Oregon Health & Science University
- Study coordinator: Messer, William
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Defining immune markers predicting protection against dengue in a long-term family study in Thailand
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.